Pfizer, Covid
Pfizer beats earnings estimates, raises outlook on cost cuts and smaller-than-feared drop in Covid drug sales
Pfizer reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefiting from its broad cost-cutting program and strong sales of its non-Covid products. The pharmaceutical giant's quarterly results also benefited from a smaller-than-feared drop in sales for its Covid antiviral pill Paxlovid.
Pfizer lifts profit view on cost cuts, demand for COVID products
Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of its COVID antiviral treatment.
Pfizer Beats Estimates for the First Quarter
The pharma giant's earnings surpassed Wall Street's expectations despite revenue declines from its COVID-19 products.
Pfizer Profits Drop On Lower Covid-19 Product Sales
Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts.
Pfizer lifts profit forecast on cost cuts, smaller drop in Covid drug demand
Pfizer lifted its annual profit forecast on Wednesday, and reported first-quarter results that topped Wall Street estimates on cost cuts, a smaller-than-feared drop in sales of its COVID antiviral treatment and strong sales of its pneumonia vaccine.
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs ...
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.
FiercePharma3d
Pfizer sets up DTC marketing platform as Q1 sales beat expectations
Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online ...
Pfizer Stock Gets Boost From Better-Than-Expected Earnings
Pfizer stock rose as markets opened Wednesday following an earnings report that included sales growth among Pfizer's ...
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the ...
Crain's New York2d
Pfizer beats earnings estimates months after stock dipped to record lows
Pfizer’s stock price rose 6% by the end of the day Wednesday to $27.18.
Buy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost Savings
Chris Shibutani, an analyst from Goldman Sachs, maintained the Buy rating on Pfizer (PFE – Research Report). The associated price target ...
MM&M2d
Rx Rundown: Pfizer, Walmart, Novartis and more
U.K.-based medical comms shop Bioscript Group acquired Enzyme Communications. The FDA approved Beqvez, Pfizer’s one-time ...
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend
Readers hoping to buy Pfizer Inc. ( NYSE:PFE ) for its dividend will need to make their move shortly, as the stock ...